Meeting
2016 Gastrointestinal Cancers Symposium
Prospective biomarker validation trial evaluating the prognostic role of the combined expression of phospho-insulin growth factor receptor-1 and matrilysin in KRAS (exon 2) wild-type (WT) metastatic colorectal cancer (mCRC) patients treated with FOLFOX-6 plus panitumumab as first-line therapy [PULSE trial (GEMCAD 09-03)].
Authors
Juan Maurel
Hospital Clinic, Barcelona, Spain
Juan Maurel , Carlos Fernandez-Martos , Marta Martin-Richard , Vicente Alonso , Jose Carlos Mendez , Antonia Salud , Carles Pericay , Jorge Aparicio , Javier Gallego , Alberto Carmona , Enrique Casado , Hermini Manzano , Carlos Horndler , Michele Rubini , Miriam Cuatrecasas , Xabier Garcia-Albeniz , Jaime Feliu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Clinical Trial Registration Number
NCT01288339
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 583)
DOI
10.1200/jco.2016.34.4_suppl.583
Abstract #
583
Poster Bd #
E10
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild‑type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC).
First Author: Lee Steven Schwartzberg
Poster
2017 Gastrointestinal Cancers Symposium
A phase Ib/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT): Biomarker substudy.
First Author: Amanda Rose Townsend
Poster
2015 Gastrointestinal Cancers Symposium
Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).
First Author: Ann-Lii Cheng
Poster
2015 Gastrointestinal Cancers Symposium
Exploratory RAS analysis of the phase Ib/II 20060447 trial of rilotumumab (R) or ganitumab (G) plus panitumumab (pmab) versus pmab alone in patients (pts) with previously treated metastatic colorectal cancer (mCRC).
First Author: Cathy Eng